BIO Looks To Colorado Task Force In Push Against Universal Vaccine Purchase Program
The biotech industry is concerned that a pending Colorado bill moves toward shifting vaccine purchases for insured patients from the private to the public sector, but supports the bill’s establishment of a task force to examine ways to increase immunization rates.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.